PT1292294E - Utilização de triglicéridos de cadeia média para tratamento e prevenção da doença de alzheimer - Google Patents

Utilização de triglicéridos de cadeia média para tratamento e prevenção da doença de alzheimer Download PDF

Info

Publication number
PT1292294E
PT1292294E PT01930965T PT01930965T PT1292294E PT 1292294 E PT1292294 E PT 1292294E PT 01930965 T PT01930965 T PT 01930965T PT 01930965 T PT01930965 T PT 01930965T PT 1292294 E PT1292294 E PT 1292294E
Authority
PT
Portugal
Prior art keywords
alzheimer
disease
prevention
treatment
medium chain
Prior art date
Application number
PT01930965T
Other languages
English (en)
Portuguese (pt)
Inventor
Samuel T Henderson
Original Assignee
Accera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22743976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1292294(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Accera Inc filed Critical Accera Inc
Publication of PT1292294E publication Critical patent/PT1292294E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT01930965T 2000-05-01 2001-05-01 Utilização de triglicéridos de cadeia média para tratamento e prevenção da doença de alzheimer PT1292294E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20098000P 2000-05-01 2000-05-01

Publications (1)

Publication Number Publication Date
PT1292294E true PT1292294E (pt) 2009-06-01

Family

ID=22743976

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01930965T PT1292294E (pt) 2000-05-01 2001-05-01 Utilização de triglicéridos de cadeia média para tratamento e prevenção da doença de alzheimer

Country Status (10)

Country Link
US (3) US20020006959A1 (https=)
EP (3) EP1292294B1 (https=)
JP (2) JP2003531857A (https=)
AT (1) ATE425750T1 (https=)
AU (1) AU2001257451A1 (https=)
DE (1) DE60138019D1 (https=)
DK (1) DK1292294T3 (https=)
ES (2) ES2752800T3 (https=)
PT (1) PT1292294E (https=)
WO (1) WO2001082928A1 (https=)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
AU2001257451A1 (en) 2000-05-01 2001-11-12 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
WO2007115282A2 (en) * 2006-04-03 2007-10-11 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US20060189545A1 (en) * 2003-03-06 2006-08-24 Henderson Samuel T Novel chemical entities and methods for their use in treatment of metabolic disorders
GB0306394D0 (en) 2003-03-20 2003-04-23 Univ Nottingham Carnitine retention
EP1648952B1 (en) 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
EP1778615A4 (en) 2004-07-20 2010-01-06 Btg Int Ltd OLIGOMERE KETONE COMPOUNDS
ES2574557T3 (es) * 2004-09-21 2016-06-20 Btg International Limited Miméticos dopaminérgicos
US7702343B2 (en) * 2005-04-04 2010-04-20 Qualcomm Incorporated Efficient gap allocation for cell measurements in asynchronous communication networks
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
FR2885491B1 (fr) * 2005-05-16 2020-03-06 Nutricos Technologies Traitement de la secheresse keratinique par des glycerides
WO2007001883A2 (en) * 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
US20070243211A1 (en) * 2005-11-07 2007-10-18 Jaffe Russell M Compositions for regulating metabolic disorders and methods of use thereof
ES2665744T3 (es) * 2005-12-15 2018-04-27 Nestec S.A. Composiciones y métodos para conservar la función cerebral
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
ES2841379T3 (es) * 2007-03-13 2021-07-08 Jds Therapeutics Llc Procedimientos y composiciones para la liberación sostenida de cromo
HRP20130551T1 (xx) 2007-03-28 2013-07-31 Aker Biomarine As Biouäśinkovite smjese kril ulja
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
CA2685380A1 (en) * 2007-05-14 2008-11-20 Neuera Pharmaceuticals, Inc. Inhibitors of acetyl-coa carboxylase for treatment of neuronal hypometabolism
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
MX2010000224A (es) 2007-06-26 2010-05-03 Nutricia Nv Mejoramiento de la memoria en individuos con mini-examen de estado mental de 24-26.
CA2853992C (en) 2007-07-31 2020-06-23 Cerecin Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
CN101951923B (zh) 2007-12-20 2013-10-30 N.V.努特里奇亚 含核苷酸/核苷的液态产品
EP2240017B1 (en) 2008-01-04 2019-03-13 Oxford University Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
US8105809B2 (en) 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
AU2009266869B2 (en) * 2008-07-03 2016-07-07 Cerecin Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
JP5789511B2 (ja) * 2008-07-18 2015-10-07 ダート ニューロサイエンス （ケイマン） エルティーディー 記憶剤の評価のための方法およびシステム
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
CA2785714C (en) * 2009-12-30 2016-01-26 Baylor Research Institute Anaplerotic therapy for alzheimer's disease and the aging brain
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
US8349376B1 (en) * 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
DK2751279T3 (da) 2011-08-31 2017-11-20 St Jude Children's Res Hospital Fremgangsmåder og sammensætninger til påvisning af niveauet af lysosomal exocytose-aktivitet og fremgangsmåder til anvendelse
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
GB201210699D0 (en) * 2012-06-15 2012-08-01 Vitaflo Ltd Nutritional food
DK2914251T3 (da) 2012-11-05 2019-11-04 Us Health Ketonlegemer til beskyttelse af væv mod beskadigelse som følge af ioniseringsstråling
ES2728727T3 (es) 2012-12-13 2019-10-28 Baylor Res Institute At Dallas Triheptanoína para el tratamiento de la deficiencia del transportador de glucosa 1
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
CA2902603C (en) 2013-03-19 2021-03-02 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
US9833430B2 (en) 2013-11-14 2017-12-05 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
AU2015217796B2 (en) * 2014-02-11 2020-04-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
CN106998748A (zh) 2014-12-08 2017-08-01 雀巢产品技术援助有限公司 用于治疗癫痫的包含中链甘油三酯的组合物和方法
US10668041B2 (en) 2014-12-08 2020-06-02 Societe Des Produits Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
WO2016128838A2 (en) 2015-02-11 2016-08-18 Aker Biomarine Antarctic As Lipid compositions
PL3256003T5 (pl) 2015-02-11 2025-11-17 Aker Biomarine Human Ingredients As Sposoby ekstrakcji lipidów
CN108348496A (zh) * 2015-12-04 2018-07-31 雀巢产品技术援助有限公司 中链三甘油酯组合物
CA3004996A1 (en) * 2015-12-04 2017-06-08 Nestec S.A. Method for improving cognition
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US10736548B2 (en) * 2016-05-18 2020-08-11 Invoy Holdings, Inc. Ketone measurement system for monitoring medical conditions
US11406616B2 (en) 2016-06-08 2022-08-09 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
JP7246843B2 (ja) * 2016-08-26 2023-03-28 日油株式会社 スポーツ飲料
IL300825A (en) 2017-03-15 2023-04-01 Cerecin Inc Pharmaceutical preparations with a high drug load of medium-length triglyceride chains and methods related thereto
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US20210186915A1 (en) * 2018-03-15 2021-06-24 Cerecin Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
KR20210135551A (ko) * 2019-03-04 2021-11-15 세레신 인코포레이티드 개선된 생체이용률을 갖는 중쇄 트리글리세라이드 제제 및 이와 관련된 방법
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
JP2023534919A (ja) * 2020-07-23 2023-08-15 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 認知機能を改善させるためのｍｃｔ配合物、並びにかかる配合物の製造及び使用方法
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
KR20230086717A (ko) * 2020-10-09 2023-06-15 세레신 인코포레이티드 약동학, 안전성 및 내약성 프로파일이 제어된 중쇄 트리글리세라이드의 전달 방법
CU24748B1 (es) 2022-11-04 2025-04-04 Centro Nac De Biopreparados Nutracéutico para la prevención y tratamiento del deterioro cognitivo
CN118340207A (zh) * 2024-05-10 2024-07-16 华中农业大学 一种防治老年痴呆症的食用油脂及其制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2766146A (en) * 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US2766145A (en) * 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US3053677A (en) * 1959-11-12 1962-09-11 Eastman Kodak Co Petroleum wax for paper coatings
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
FR2490631A1 (fr) * 1980-09-24 1982-03-26 Roussel Uclaf Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique
US4528197A (en) 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4551523A (en) * 1983-04-14 1985-11-05 Eastman Kodak Company Preparation of saccharide acetoacetates
US4847296A (en) 1984-09-13 1989-07-11 Babayan Vigen K Triglyceride preparations for the prevention of catabolism
US5126373A (en) 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
SE8803141L (sv) 1988-09-07 1990-03-08 Kabivitrum Ab Naeringsmedel foer maenniskor och djur
US5650148A (en) 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
DE3843238C1 (https=) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
IT1240775B (it) 1990-02-23 1993-12-17 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil-l-carnitine con l'acido beta-idrossibutirrico e composizioni farmaceutiche che li contengono per la inibizione della degenerazione neuronale, della proteolisi epatica e nel trattamento del coma.
WO1991015963A1 (en) 1990-04-26 1991-10-31 The Procter & Gamble Company Shortening compositions containing polyol fatty acid polyesters
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5538983A (en) 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
GB9113484D0 (en) 1991-06-21 1991-08-07 Unilever Plc Cosmetic composition
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
JP3486778B2 (ja) 1993-04-02 2004-01-13 三菱ウェルファーマ株式会社 アルツハイマー病予防治療剤
US5420335A (en) 1993-09-30 1995-05-30 Birkhahn; Ronald H. Parenteral nutrients based on watersoluble glycerol bisacetoacetates
US5438042B1 (en) * 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
JP3645580B2 (ja) 1993-10-22 2005-05-11 株式会社フジモト・ブラザーズ グルコースエステル誘導体を含有する脳代謝改善剤
US5691325A (en) 1994-01-14 1997-11-25 Sandyk; Reuven Method for ameliorating age-related disease conditions
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US7049078B2 (en) * 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
US5607967A (en) 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
AU4151996A (en) 1994-11-08 1996-05-31 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US5936078A (en) 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
DE19609476A1 (de) * 1996-03-11 1997-09-18 Basf Ag Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen
IT1284650B1 (it) 1996-05-24 1998-05-21 Sigma Tau Ind Farmaceuti Farmaco a base di un derivato della carnitina per il trattamento della demenza di alzheimer in pazienti ad insorgenza precoce della patologia
KR980008239A (ko) * 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6316038B1 (en) * 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
CN1315473C (zh) * 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
US6352722B1 (en) 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
CA2327095A1 (en) 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
DE69922206T2 (de) 1998-07-22 2005-11-24 Metabolix, Inc., Cambridge Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere
GB2341389B (en) * 1998-09-14 2000-07-12 Pan Pacific Pharmaceuticals In Useful properties of a bee venom protein and gene encoding same
DK1123094T3 (da) * 1998-09-15 2007-08-20 Btg Int Ltd Terapeutiske præparater (II)
GB9908202D0 (en) 1999-04-12 1999-06-02 Unilever Plc Cosmetic compositions
WO2007115282A2 (en) * 2006-04-03 2007-10-11 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
AU2001257451A1 (en) 2000-05-01 2001-11-12 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
DE20012857U1 (de) * 2000-07-27 2000-11-09 Sportmedizin Team Vertriebs Gmbh, Berneck Diätetisches Lebensmittel zum Fettabbau
US6667397B2 (en) 2000-08-25 2003-12-23 Eastman Chemical Company Methods of preparing disaccharide and trisaccharide C6-C12 fatty acid esters with high alpha content and materials therefrom
GB2368011A (en) 2000-10-17 2002-04-24 Unilever Plc Fatty acid esters of maltose and uses thereof
US20020103139A1 (en) * 2000-12-01 2002-08-01 M. Weisspapir Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control
JP2004517109A (ja) 2000-12-30 2004-06-10 エルジー ハウスホールド アンド ヘルスケア カンパニー．， リミテッド． グルコースアシル化誘導体またはシュークロースアシル化誘導体を含有する皮膚美白剤｛Ｃｏｓｍｅｔｉｃｆｏｒｓｋｉｎｗｈｉｔｅｎｉｎｇｃｏｎｔａｉｎｉｎｇａｃｙｌｓｕｂｓｔｉｔｕｔｅｄｄｅｒｉｖａｔｉｖｅｓｏｆｇｌｕｃｏｓｅｏｒｓｕｃｒｏｓｅ｝
JP2004534050A (ja) * 2001-06-07 2004-11-11 エーザイ株式会社 細胞ストレスに関連する疾病及び状態を予防及び治療する方法
AU2002336759A1 (en) * 2001-09-21 2003-04-14 Accera, Inc. Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
WO2004021980A2 (en) * 2002-09-09 2004-03-18 Mitochroma Research, Inc. Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation
US6884454B2 (en) 2002-10-21 2005-04-26 Julio Lionel Pimentel Appetite suppressing diet bar
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20060189545A1 (en) 2003-03-06 2006-08-24 Henderson Samuel T Novel chemical entities and methods for their use in treatment of metabolic disorders
EP1648952B1 (en) * 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
US20050013884A1 (en) * 2003-07-16 2005-01-20 Rennels M. Scott Compositions and methods for treating heart disease
US7148192B2 (en) 2004-01-29 2006-12-12 Ebwe Pharma Ges. M.H. Nfg.Kg Neuroprotective dietary supplement
US20060252775A1 (en) 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
ES2665744T3 (es) 2005-12-15 2018-04-27 Nestec S.A. Composiciones y métodos para conservar la función cerebral
US7807718B2 (en) 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose

Also Published As

Publication number Publication date
AU2001257451A8 (en) 2006-11-09
WO2001082928A9 (en) 2006-06-15
EP1292294A4 (en) 2004-04-14
ES2752800T3 (es) 2020-04-06
WO2001082928A1 (en) 2001-11-08
US8426468B2 (en) 2013-04-23
JP2012188431A (ja) 2012-10-04
EP1292294A1 (en) 2003-03-19
JP5701245B2 (ja) 2015-04-15
JP2003531857A (ja) 2003-10-28
ATE425750T1 (de) 2009-04-15
DK1292294T3 (da) 2009-06-22
AU2001257451A1 (en) 2001-11-12
EP1292294B1 (en) 2009-03-18
EP2065041B1 (en) 2019-07-31
US20020006959A1 (en) 2002-01-17
US20120196932A1 (en) 2012-08-02
EP2319508A1 (en) 2011-05-11
US20060122270A1 (en) 2006-06-08
EP2065041A1 (en) 2009-06-03
DE60138019D1 (de) 2009-04-30
ES2323940T3 (es) 2009-07-28

Similar Documents

Publication Publication Date Title
PT1292294E (pt) Utilização de triglicéridos de cadeia média para tratamento e prevenção da doença de alzheimer
ATE374029T1 (de) Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
EP1474158A4 (en) PREVENTING AND TREATING OXIDATIVE STRESS RELATED DISORDERS USING GLUTATHIONE AND PHASE II DETOXIFICATION ENZYMES
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
WO1998020864A3 (en) Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
TW264480B (https=)
HUT62337A (en) New cyclosporins, pharmaceutical compositions comprising such compounds and process for producing same
TNSN04082A1 (en) N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives
GB0108592D0 (en) Therapeutic agents
IL143921A0 (en) Compositions for the treatment and prevention of tumors and tumor-related disorders
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2004077938A3 (en) Novel chemical entities and methods for their use in treatment of metabolic disorders
HU9700598D0 (en) Process for profilacting and treating pancreatitis
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
EE03953B1 (et) 2-fenüül-1,2-bensisoseleenasool-3(2H)-ooni kasutamine farmatseutilise preparaadi valmistamisel Alzheimeri tõve raviks
BR0314541A (pt) Tratamento de demência e doença de parkinson
IL125660A0 (en) Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture
IL111922A0 (en) Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylates, their preparation and pharmaceutical com¦ositions containing them
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
DE59409129D1 (de) Verwendung von lithiumverbindungen zur behandlung und prophylaxe des morbus alzheimer
BR9900024A (pt) Biciclo[3.1.0]hexanos e compostos relacionados.
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії